Orexo Reaches Agreement in Principle with US Department of Justice
Swedish pharmaceutical company Orexo AB announced it has reached a non-binding agreement in principle with the U.S. Department of Justice. The agreement outlines the key terms for settling an ongoing investigation.
Orexo AB, a Swedish pharmaceutical company, has reached a non-binding agreement in principle with the U.S. Department of Justice (DOJ) concerning the main elements of a settlement. This development indicates progress in resolving an investigation that the company has been subject to.
The company stated that it is in the final stages of finalizing the terms of this agreement. While specific details have not yet been disclosed, the agreement is expected to address the core issues related to the investigation into Orexo's commercial practices in the United States.
Orexo has not provided further information regarding the financial or legal implications of the proposed settlement, only noting that the terms are "negotiable." The company anticipates concluding a definitive agreement in the near future.
The company's focus is on developing and marketing treatments for opioid dependence and pain. Orexo has been working to expand its presence in the U.S. market over the past several years.